Natera has announced findings from a study evaluating its Signatera in individuals with soft tissue and bone sarcomas.

The Final Rule was mooted for implementation over a staged transition period, determined by a service’s risk level, by 2028.

Firefly Neuroscience has completed the acquisition of Evoke Neuroscience, a developer of technologies aimed at assessing ...

URA has entered the consumer diabetes space, offering a new glucose feature for its ring that uses insights from Dexcom’s CGM ...

InBrain Neuroelectronics has won a €4m ($4.5m) grant from the Spanish Ministry of Industry and Tourism to develop its BCI ...

The US Food and Drug Administration (FDA) has granted 510(k) clearance to GE HealthCare's Aurora nuclear medicine system and ...

Tariffs, though designed as economic tools, have ripple effects that extend deeply into the regulatory framework of the ...